Prostate cancer in Saskatchewan Canada, before and during the PSA era
Prostate cancer in Saskatchewan Canada, before and during the PSA era
复制标题
PSA 时代之前和期间加拿大萨斯喀彻温省的前列腺癌
DOI：
10.1023/a:1008965617078
复制
发表时间：
2004
影响因子：
2.3
通讯作者：
J. Tonita
中科院分区：
文献类型：
--
作者：
D. Skarsgard;J. Tonita
目的：本研究的目的是描述 1990 年萨斯喀彻温省引入前列腺特异性抗原 (PSA) 检测期间前列腺癌发病率、诊断病例生存率以及前列腺癌特异性死亡率的变化。方法：1970 年至 1997 年期间在萨斯喀彻温省诊断的所有前列腺肿瘤 (ICD-O = C61.9) 病例均在萨斯喀彻温省癌症中心发现登记处。定义了腺癌亚组以供进一步研究。根据诊断时间段计算年龄调整后的发病率和特定年龄的发病率以及精算生存率和相对生存率。还使用生命统计数据计算了每个时间段的前列腺癌年龄调整死亡率和年龄特异性死亡率。结果：1970年，年龄调整后的前列腺癌发病率为每105人中60.5人，1989年逐渐上升至每105人中101.5人。1990年，发病率上升得更加急剧，1993年达到每105人中163.1人的峰值，此后开始出现这种情况。跌倒。这一急剧增长与 PSA 测试在该省的引入和使用增加同时发生。前列腺癌患者的相对生存率从 20 世纪 70 年代末到 1980 年代保持稳定，然后在 1990-94 年间显着改善。引入PSA检测后，前列腺癌患者的相对死亡风险仅为过去15年的60%左右。从 20 世纪 80 年代初到研究期末，前列腺癌特异性死亡率没有变化。结论：上述数据与 PSA 筛查导致的前列腺癌早期诊断一致。由于死亡率尚未改变，因此建议对无症状男性进行广泛筛查还为时过早。
Objectives: The purpose of this study was to describe changes in the incidence of prostate cancer and in survival of diagnosed cases, as well as prostate cancer-specific mortality, during a period spanning the introduction of prostate specific antigen (PSA) testing in Saskatchewan in 1990.Methods: All cases of neoplasms of the prostate (ICD-O = C61.9) diagnosed in Saskatchewan from 1970 to 1997 inclusive, were identified in the Saskatchewan Cancer Registry. A subgroup of adenocarcinomas was defined for further study. Age-adjusted and age-specific incidence rates, and actuarial and relative survival were calculated according to time period of diagnosis. Age-adjusted and age-specific mortality rates from prostate cancer were also calculated for each time period, using Vital Statistics data.Results: The age-adjusted incidence of prostate cancer was 60.5 per 105 in 1970, rising gradually to 101.5 per 105 in 1989. In 1990, incidence rose much more sharply, reaching a peak of 163.1 per 105in 1993, after which it began to fall. This sharp increase coincided with the introduction and increasing use of the PSA test in the province. Relative survival of prostate cancer patients was stable from the late 1970s through the 1980s, then improved markedly in the 1990–94 period. After the introduction of the PSA test, the relative risk of death for prostate cancer patients was only about 60% of what it had been throughout the previous 15 years. Prostate cancer-specific death rates did not change from the early 1980s to the end of the study period.Conclusions: The above data are consistent with earlier diagnosis of prostate cancer due to PSA screening. Because mortality has not yet changed, it is premature to recommend widespread screening of asymptomatic men.
DOI：
10.1001/jama.1993.03500200047031
发表时间：
1993-05
期刊：
JAMA
影响因子：
--
作者：
Grace L. Lu-Yao;D. McLerran;J. Wasson;J. Wennberg;T. Bubolz;Catherine C. Lindsay;B. Littenberg;A. Flood;Chiang-Hua Chang;A. Mulley;M. J. Barry;C. Coley;F. J. Fowler;R. Bruskewitz;P. Albertson;C. Fleming
通讯作者：
Grace L. Lu-Yao;D. McLerran;J. Wasson;J. Wennberg;T. Bubolz;Catherine C. Lindsay;B. Littenberg;A. Flood;Chiang-Hua Chang;A. Mulley;M. J. Barry;C. Coley;F. J. Fowler;R. Bruskewitz;P. Albertson;C. Fleming
影响因子：
6.6
作者：
PARTIN, AW;CARTER, HB;WALSH, PC
通讯作者：
WALSH, PC
影响因子：
5
作者：
Ruth Etzioni;R. Cha;E. Feuer;O. Davidov
通讯作者：
Ruth Etzioni;R. Cha;E. Feuer;O. Davidov